Our SMEs' deep dive into the CDMO sector based on data from 400+ global providers
Exploration of the impact of economic volatility, therapeutic pipeline trends, and geopolitical disruptions on outsourcing strategies
Modality-by-modality breakdown — from small molecules and ADCs to cell and gene therapies
Single source for data, context, and forecasts you need to navigate the CDMO space in 2025 and beyond
Our SMEs’ examination of the full pharma and biopharma development and manufacturing landscape, segmented into 10 distinct modalities.
Analyses of how US tariffs and other global economic factors may influence the CDMO market, and their impact on innovation.
How the increasing complexities of pharmaceutical manufacturing are impacting staffing for technical and operations specialists in life sciences.
Global Therapeutic Pipeline
Funding Landscape Examination
International CDMO Assessment
Exploration of Evolving Trade Policies
Changes in the CDMO Workforce
Predictions for 2025 and Beyond
Over 1,000 hours of data collection and analysis
including interviews with CDMO owners, PhDs and customers.